With regard to the clinical appropriateness of the use of these medicines, a Swedish study based on national registry data estimated around 50–80% of people with T2D would be eligible to receive either SGLT2i or GLP1-RA based on 2019 clinical guideline recommendations [27]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.